世界の臨床試験市場2021-2028:フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV)、研究デザイン別(介入、観察、拡張アクセス)、疾患別、地域別

◆英語タイトル:Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, By Region, And Segment Forecasts, 2021 - 2028
◆商品コード:GV21FB037
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2021年1月25日
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥678,300見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥792,300見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,020,300見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

グランドビューリサーチ社は、世界の臨床試験市場規模が2028年までに695憶ドルに達すると予測しています。2021年から2028年までに年平均5.7%成長する見通しです。本調査レポートでは、臨床試験の世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV)分析、研究デザイン別(介入、観察、拡張アクセス)分析、疾患別(自己免疫/炎症、疼痛管理、腫瘍、中枢神経症状、糖尿病)分析、地域別分析、競争状況などを掲載しています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・臨床試験の世界市場規模:フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV)
・臨床試験の世界市場規模:研究デザイン別(介入、観察、拡張アクセス)
・臨床試験の世界市場規模:疾患別(自己免疫/炎症、疼痛管理、腫瘍、中枢神経症状、糖尿病)
・臨床試験の世界市場規模:地域別
・競争状況
【レポートの概要】

Clinical Trials Market Growth & Trends

The global clinical trials market size is expected to reach USD 69.5 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.7% from 2021 to 2028. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and other products. Also, clinical studies have become increasingly costly ventures, adding to the overall cost of developing a drug. Hence, big pharmaceuticals as well as small biotechnology firms are looking for innovative ways to improve research outcomes and decrease research costs.

The increasing need to develop new therapeutics for chronic diseases such as cancer, respiratory disorder, diabetes, cardiovascular disease, and others is creating immense pressure on healthcare. The global pandemic caused due to COVID-19 and the increasing demand for developing a suitable treatment for the same is driving the market’s growth. The number of people affected by the coronavirus has reached one million, which further depicts an increasing need for therapeutics and vaccines. Currently, there are 288 therapeutics and 106 vaccines in development. Out of this, nearly 7.0% therapeutics are in Phase IV, 21.0% in Phase III, 43.0% & 13.0% in Phase II & Phase I respectively.

The pandemic has also resulted in global disruption of traditional onsite clinical studies. Hence, the regulatory bodies all over the world have launched various initiatives for fast-tracking clinical studies for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the WHO to find effective treatment against COVID-19.

Though COVID-19 is forcing many medical device and drug developers to revise the approach they prepare for these types of crises, integrating best practices within clinical trial procedures and adapting to virtual studies can support continuous development of therapeutics even in the presence of this pandemic.

Clinical Trials Market Report Highlights

• Phase III clinical trials dominated the market with a share of 53.2% in 2020. This is attributed to the complexity level associated with this phase

• Interventional design segment accounted for the largest share of 45.6% in 2020 in the study design segment owing to the increasing demand for the intervention for clinical studies by researchers

• North America held 51.0% of the market share in 2020. Favorable government initiatives and presence of large numbers of players in the U.S. offerings advanced services are responsible for market growth

• In Asia Pacific, the market is expected to witness the fastest CAGR of 6.7% over the forecast period owing to the increasing patient pool and cost efficient services

【レポートの目次】

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Phase
1.1.2. Study Design
1.1.3. Indication
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1: Understanding the market dynamics
1.9.2. Objective 2: Understanding the market estimates and forecasts
1.9.3. Objective 3: Understanding the attributes such as strategy framework, competitor categorization
1.9.4. Objective 4: Understanding the key product and application scopes to conclude on the market size
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Product Pipeline Analysis, by Stage
3.3.1. Therapeutics in development
3.3.2. Vaccines in development
3.4. Fast track of clinical trials
3.4.1. FDA initiative – CTPA
3.4.2. U.K. initiative – ACCORD
3.4.3. ASIA Pacific initiative – DCGI
3.4.4. University of Pittsburgh School of Medicine – UPMC
3.5. Solidarity clinical trials
3.5.1. Participation in solidarity trials
3.5.2. Solidarity clinical trial for vaccines
3.6. Virtual clinical trials
3.6.1. In – home clinical services
3.7. COVID – 19 impact on clinical trials
3.7.1. Companies with phase 1 trial disruption
3.7.2. Companies with phase 2 trial disruption
3.7.3. Companies with phase 3 trial disruption
3.8. Market Dynamics
3.8.1. Market Driver Analysis
3.8.1.1. Increasing research and development promoting outsourcing
3.8.1.2. Adoption of new technology in clinical research
3.8.1.3. Increasing prevalence of chronic disease
3.8.1.4. Globalization of clinical trials
3.8.2. Market Restraint Analysis
3.8.2.1. Stringent regulatory policies for patient enrollment
3.8.2.2. Lack of skilled workforce in clinical research
3.8.3. Industry Challenges
3.8.3.1. Rising cost of clinical trial
3.9. Clinical Trials: Market Analysis Tools
3.9.1. Industry Analysis – Porter’s
3.9.1.1. Supplier Power
3.9.1.2. Buyer Power
3.9.1.3. Substitution Threat
3.9.1.4. Threat from new entrant
3.9.1.5. Competitive rivalry
3.9.2. PESTEL Analysis
3.9.2.1. Political Landscape
3.9.2.2. Environmental Landscape
3.9.2.3. Social Landscape
3.9.2.4. Technology Landscape
3.9.2.5. Legal Landscape
3.9.3. Major Deals & Strategic Alliances Analysis
Chapter 4. Clinical Trials Market: Segment Analysis, By Phase, 2016 – 2028 (USD Million)
4.1. Definitions & Scope
4.2. Phase market share analysis, 2020 & 2028
4.3. Segment Dashboard
4.4. Global Clinical Trials Market, by Phase, 2016 to 2028
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
4.5.1. Phase I
4.5.2. Phase II
4.5.3. Phase III
4.5.4. Phase IV
Chapter 5. Clinical Trials Market: Segment Analysis, By Study Design, 2016 – 2028 (USD Million)
5.1. Definitions & Scope
5.2. Study Design Market Share Analysis, 2020 & 2028
5.3. Segment Dashboard
5.4. Global Clinical Trials Market, By Study Design, 2016 to 2028
5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
5.5.1. Interventional
5.5.2. Observational
5.5.3. Expanded Access
Chapter 6. Clinical Trials Market: Segment Analysis, By Indication, 2016 – 2028 (USD Million)
6.1. Definitions & Scope
6.2. Indication Market Share Analysis, 2020 & 2028
6.3. Segment Dashboard
6.4. Global Clinical Trials Market, By Indication, 2016 to 2028
6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
6.5.1. Autoimmune/inflammation
6.5.2. Pain management
6.5.3. Oncology
6.5.4. CNS condition
6.5.5. Diabetes
6.5.6. Obesity
6.5.7. Cardiovascular
6.5.8. Others
Chapter 7. Clinical Trials Market: Regional Market Analysis, By Phase, 2016 – 2028 (USD Million)
7.1. Definitions & Scope
7.2. Regional Market Share Analysis, 2020 & 2028
7.3. Regional Market Dashboard
7.4. Regional Market Share, 2020
7.5. Market Size, & Forecasts, and Trend Analysis, 2016 to 2028:
7.6. North America
7.6.1. Market estimates and forecast, by country, 2016 – 2028 (USD Million)
7.6.2. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.6.3. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.6.4. Market estimates and forecast, By Indication, 2016 – 2028 (USD Million)
7.6.5. U.S.
7.6.5.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.6.5.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.6.5.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.6.6. Canada
7.6.6.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.6.6.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.6.6.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.7. Europe
7.7.1. Market estimates and forecast, by country, 2016 – 2028 (USD Million)
7.7.2. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.7.3. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.7.4. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.7.5. Germany
7.7.5.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.7.5.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.7.5.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.7.6. U.K.
7.7.6.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.7.6.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.7.6.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.7.7. France
7.7.7.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.7.7.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.7.7.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.7.8. Italy
7.7.8.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.7.8.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.7.8.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.7.9. Spain
7.7.9.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.7.9.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.7.9.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.8. Asia Pacific
7.8.1. Market estimates and forecast, by country, 2016 – 2028 (USD Million)
7.8.2. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.8.3. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.8.4. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.8.5. China
7.8.5.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.8.5.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.8.5.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.8.6. Japan
7.8.6.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.8.6.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.8.6.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.8.7. India
7.8.7.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.8.7.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.8.7.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.8.8. Australia
7.8.8.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.8.8.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.8.8.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.8.9. South Korea
7.8.9.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.8.9.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.8.9.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.9. Latin America
7.9.1. Market estimates and forecast, by country, 2016 – 2028 (USD Million)
7.9.2. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.9.3. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.9.4. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.9.5. Brazil
7.9.5.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.9.5.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.9.5.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.9.6. Mexico
7.9.6.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.9.6.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.9.6.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.9.7. Argentina
7.9.7.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.9.7.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.9.7.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.9.8. Colombia
7.9.8.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.9.8.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.9.8.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.10. Middle East and Africa
7.10.1. Market estimates and forecast, by country, 2016 – 2028 (USD Million)
7.10.2. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.10.3. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.10.4. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.10.5. South Africa
7.10.5.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.10.5.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.10.5.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.10.6. Saudi Arabia
7.10.6.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.10.6.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.10.6.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
7.10.7. UAE
7.10.7.1. Market estimates and forecast, by phase, 2016 – 2028 (USD Million)
7.10.7.2. Market estimates and forecast, by study design, 2016 – 2028 (USD Million)
7.10.7.3. Market estimates and forecast, by indication, 2016 – 2028 (USD Million)
Chapter 8. Clinical Trials Market – Competitive Analysis
8.1. Key companies profiled
8.1.1. IQVIA
8.1.1.1. Company Overview
8.1.1.2. Financial Performance
8.1.1.3. Product Benchmarking
8.1.1.4. Strategic Initiatives
8.1.2. PAREXEL International Corporation
8.1.2.1. Company Overview
8.1.2.2. Financial Performance
8.1.2.3. Product Benchmarking
8.1.2.4. Strategic Initiatives
8.1.3. Pharmaceutical Product Development, LLC
8.1.3.1. Company Overview
8.1.3.2. Financial Performance
8.1.3.3. Product Benchmarking
8.1.3.4. Strategic Initiatives
8.1.4. Charles River Laboratory
8.1.4.1. Company Overview
8.1.4.2. Financial Performance
8.1.4.3. Product Benchmarking
8.1.4.4. Strategic Initiatives
8.1.5. ICON Plc
8.1.5.1. Company Overview
8.1.5.2. Financial Performance
8.1.5.3. Product Benchmarking
8.1.5.4. Strategic Initiatives
8.1.6. Wuxi AppTec Inc
8.1.6.1. Company Overview
8.1.6.2. Financial Performance
8.1.6.3. Product Benchmarking
8.1.6.4. Strategic Initiatives
8.1.7. PRA Health Sciences
8.1.7.1. Company Overview
8.1.7.2. Financial Performance
8.1.7.3. Product Benchmarking
8.1.7.4. Strategic Initiatives
8.1.8. SGS SA
8.1.8.1. Company Overview
8.1.8.2. Financial Performance
8.1.8.3. Product Benchmarking
8.1.8.4. Strategic Initiatives
8.1.9. Syneos Health
8.1.9.1. Company Overview
8.1.9.2. Financial Performance
8.1.9.3. Product Benchmarking
8.1.9.4. Strategic Initiatives
8.1.10. Chiltern International Ltd
8.1.10.1. Company Overview
8.1.10.2. Financial Performance
8.1.10.3. Product Benchmarking
8.1.10.4. Strategic Initiatives
8.1.11. Eli Lilly and Company
8.1.11.1. Company Overview
8.1.11.2. Financial Performance
8.1.11.3. Product Benchmarking
8.1.11.4. Strategic Initiatives
8.1.12. Novo Nordisk A/S
8.1.12.1. Company Overview
8.1.12.2. Financial Performance
8.1.12.3. Product Benchmarking
8.1.12.4. Strategic Initiatives
8.1.13. Pfizer
8.1.13.1. Company Overview
8.1.13.2. Financial Performance
8.1.13.3. Product Benchmarking
8.1.13.4. Strategic Initiatives
8.1.14. Clinipace
8.1.14.1. Company Overview
8.1.14.2. Financial Performance
8.1.14.3. Product Benchmarking
8.1.14.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Clinical Trials Market, By Region 2016 - 2028 (USD Million)
Table 4 Global Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 5 Global Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 6 Global Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 7 North America Clinical Trials Market, By Country, 2016 - 2028 (USD Million)
Table 8 North America Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 9 North America Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 10 North America Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 11 U.S. Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 12 U.S. Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 13 U.S. Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 14 Canada Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 15 Canada Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 16 Canada Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 17 Europe Clinical Trials Market, By Country, 2016 - 2028 (USD Million)
Table 18 Europe Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 19 Europe Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 20 Europe Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 21 U.K. Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 22 U.K. Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 23 U.K. Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 24 Germany Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 25 Germany Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 26 Germany Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 27 France Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 28 France Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 29 France Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 30 Italy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 31 Italy Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 32 Italy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 33 Spain Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 34 Spain Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 35 Spain Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 36 Asia Pacific Clinical Trials Market, By Country, 2016 - 2028 (USD Million)
Table 37 Asia Pacific Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 38 Asia Pacific Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 39 Asia Pacific Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 40 India Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 41 India Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 42 India Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 43 Japan Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 44 Japan Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 45 Japan Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 46 China Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 47 China Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 48 China Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 49 Australia Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 50 Australia Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 51 Australia Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 52 South Korea Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 53 South Korea Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 54 South Korea Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 55 Latin America Clinical Trials Market, By Country, 2016 - 2028 (USD Million)
Table 56 Latin America Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 57 Latin America Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 58 Latin America Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 59 Brazil Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 60 Brazil Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 61 Brazil Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 62 Mexico Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 63 Mexico Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 64 Mexico Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 65 Argentina Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 66 Argentina Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 67 Argentina Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 68 Colombia Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 69 Colombia Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 70 Colombia Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 71 MEA Clinical Trials Market, By Country, 2016 - 2028 (USD Million)
Table 72 MEA Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 73 MEA Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 74 MEA Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 75 South Africa Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 76 South Africa Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 77 South Africa Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 78 Saudi Arabia Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 79 Saudi Arabia Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 80 Saudi Arabia Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 81 UAE Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 82 UAE Clinical Trials Market, By Study Design, 2016 - 2028 (USD Million)
Table 83 UAE Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value - chain - based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Clinical Trials Market:Market snapshot
Fig. 9 Clinical Trials Market:Market segmentation
Fig. 10 Clinical Trials Market Strategy framework
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Clinical Trials Market driver impact
Fig. 14 Clinical Trials Market restraint impact
Fig. 15 Clinical Trials Market porter’s five forces analysis
Fig. 16 Clinical Trials Market PESTEL analysis
Fig. 17 Clinical Trials Market segment dashboard
Fig. 18 Clinical Trials Market: Phase movement Analysis
Fig. 19 Phase I estimates and forecast, 2016 - 2028 (USD Million)
Fig. 20 Phase II estimates and forecast, 2016 - 2028 (USD Million)
Fig. 21 Phase III estimates and forecast, 2016 - 2028 (USD Million)
Fig. 22 Phase IV estimates and forecast, 2016 - 2028 (USD Million)
Fig. 23 Clinical Trials Market segment dashboard
Fig. 24 Clinical Trials Market: Study Design Movement Analysis
Fig. 25 Interventional market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 26 Observational market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 27 Expanded Access market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 28 Clinical Trials Market: Segment dashboard
Fig. 29 Clinical Trials Market: Indication movement analysis
Fig. 30 Autoimmune/inflammation market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 31 Pain management market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 32 Oncology market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 33 CNS condition market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 34 Diabetes market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 35 Obesity market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 36 Cardiovascular market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 37 Others market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 38 Global Clinical Trials Market: Regional movement analysis
Fig. 39 Global Clinical Trials Market: Regional outlook and key takeaways
Fig. 40 Global market share, by region
Fig. 41 North America market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 42 U.S. market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 43 Canada market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 44 Europe market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 45 U.K. market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 46 Germany market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 47 France market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 48 Italy market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 49 Spain market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 50 Asia Pacific market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 51 China market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 52 Japan market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 53 India market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 54 Australia market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 55 South Korea market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 56 Latin America market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 57 Brazil market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 58 Mexico market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 59 Argentina market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 60 Colombia market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 61 Middle East and Africa. market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 62 South Africa market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 63 Saudi Arabia market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 64 UAE market estimates and forecast, 2016 - 2028 (USD Million)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の臨床試験市場2021-2028:フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV)、研究デザイン別(介入、観察、拡張アクセス)、疾患別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆